— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.'s ("Evofem") (OTCQB:EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substit

SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe

This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women's health, spanning endometriosis to ovarian cancer, and in men's health starting with prostate cancer Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired MDNA Life Sciences Inc.'s ("MDNA") proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta's dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. Th

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. ("Pearsanta"), public via a proposed initial public offering ("IPO") in 2025. This decision aligns with Aditxt's mission to secure and develop transformative health innovations, positioning them for accelerated growth and broader market impact. Pearsanta, a precision diagnostic company, has advanced its development and operational capabilities, particularly in early cancer detection, by leveraging its proprietary Mitomic® Tec

Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. ("Adimune"), has successfully completed all preclinical efficacy and safety studies for its antigen-specific gene therapy, ADI-100. This achievement represents a major milestone as Adimune prepares to submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application to initiate first-in-human clinical trials for ADI-100 in the treatment of Type

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court's approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce receipt of the final order of the Ontario Superior Court of Justice (Commercial List) for the plan of arrangement (the "Arrangement") pursuant to which Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt"), through its wholly-owned subsidiary, Adivir, In

— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for ATI-1801 NDA Submission HALIFAX, Nova Scotia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the second quarter of its fiscal year 2025, which ended on Septem

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit ("ELOC") and At-the-Market ("ATM") facility, as well as its outstanding number of shares. Equity Issuance Update as of End of Day November 7, 2024: Total number of shares traded since ELOC and ATM Activation: 153,085,471 Total number of shares sold via ELOC and ATM: 11,920,744, representing approximately 8% of total traded shares

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) ("Appili"). Shareholders of Appili overwhelmingly voted in favor of a plan of arrangement for Aditxt to acquire all issued and outstanding Class A common shares of Appili. For additional information and results of Appili's special meeting of shareholders, please visit this link. About Appili Therapeutics Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its special meeting of shareholders held earlier today (the "Meeting"). Shareholders of the Company (the "Shareholders"), overwhelmingly voted in favour of a special resolution approving a plan of arrangement pursuant to which Aditxt Inc. (NASDAQ:ADTX) ("Aditxt"), through its wholly-owned subsidiary, Adivir, Inc. will acq

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM), has secured voting agreements with certain of its investors to ensure they will vote in favor of the merger proposal at Evofem's upcoming Special Meeting of Stockholders (the "Special Meeting"). "We believe that the proposed merger represents a compelling opportunity to accelerate Evofem's growth trajectory in women's sexual and reproductive health as a subsidiary of Aditxt," said Saundra Pelletier, CEO of Evofem. "We are making steady progress towards comp

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) ("Appili"), announcing that the U.S. Food and Drug Administration ("FDA") has provided positive feedback regarding the development strategy for ATI-1801. For additional information, please visit https://finance.yahoo.com/quote/APLIF/news/. About Appili Therapeutics, Inc. Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfil its mission of solving life

Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy

Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company's wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie's appointment is intended to accelerate the commercial launch of Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business ("B2B") and direct-to-consumer ("DTC") clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers. "Naming Ernie as

AditxtScore™ continued driving revenue growth in 2022 by adding to its expanding customer base of large physician networks, healthcare systems, independent laboratories, and employer-sponsored programs. Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ("Pearsanta"), to accelerate the growth of Aditxt's second program, AditxtScore™, through future strategic revenue and growth-oriented transactions. Anthony Voorhies, currently the head of the AditxtScore™ division, will s

Completion of GMP Drug Substances in January for Clinical Trials in H2, 2023 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for ty

Aditxt, Inc. ("Aditxt, or the "Company"). (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company's CEO, Amro Albanna, to execute Aditxt's business strategy. Thomas J. Farley, who has served as Controller and Principal Accounting Officer of Aditxt, has been appointed as CFO. As CFO of Aditxt since July 2020, Ms. Pankovcin, along with the Company's CEO and executive team, has effectively managed the Company's growth as it became publicly traded on

As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development Aditx Therapeutics, Inc. ("Aditxt") (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director. "As a new independent director of Aditxt's board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals," said Amro Albanna, co-founder and CEO of Aditxt. "We look forward to working with Dr. Chung as we establish our portfolio of fi

Dr. Tyan Will Lead and Advance Organ Transplantation Therapeutic Program Mountain View, CA, Jan. 29, 2021 (GLOBE NEWSWIRE) --  via NewMediaWire-- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation. In this role, Dr. Tyan will be overseeing Aditxt’s therapeutic program for organ rejection including advancing current candidates towards clinical trials and developing new products for new applica

4 - Aditxt, Inc. (0001726711) (Issuer)

3 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

SC 13G - Aditxt, Inc. (0001726711) (Subject)

SC 13G - Aditxt, Inc. (0001726711) (Subject)

SC 13G - Aditxt, Inc. (0001726711) (Subject)

SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

SC 13G - Aditxt, Inc. (0001726711) (Subject)

PRER14A - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)

PRE 14A - Aditxt, Inc. (0001726711) (Filer)

8-K/A - Aditxt, Inc. (0001726711) (Filer)

8-K/A - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)

10-Q - Aditxt, Inc. (0001726711) (Filer)

NT 10-Q - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)